VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of the Medical University of Vienna, who gave Oncology Times reporter Sarah Maxwell the latest data on the clinical potential of bone-directed therapies.
You may also like...
Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases 15 Apr, 2007 Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer 1 Oct, 2007 Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer 27 Oct, 2018 Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008
- Previous story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- Next story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014